Pemetrexed in bladder, head and neck, and cervical cancers

Area of Science:

• Oncology
• Pharmacology

Background:

• Pemetrexed is a novel multitargeted antifolate analog.
• It demonstrates activity across various solid tumors, notably cervix, head and neck, and bladder carcinomas.

Purpose of the Study:

• This review focuses on pemetrexed's efficacy and toxicity in specific solid tumors.
• To evaluate the role of nutritional supplementation in mitigating pemetrexed-induced toxicity.

Main Methods:

• Review of existing literature on pemetrexed in cervix, head and neck, and bladder cancers.
• Analysis of toxicity profiles and impact of folic acid and vitamin B12 supplementation.

Main Results:

• Pemetrexed exhibits encouraging activity in the studied tumor types.
• Hematologic toxicity is a significant concern in these patient populations.
• Folic acid and vitamin B12 supplementation effectively reduces severe toxicity.

Conclusions:

• Nutritional supplementation may optimize the therapeutic index of pemetrexed.
• Further randomized phase III studies are required to define pemetrexed's role in managing these cancers.